Global lower-middle market M&A Advisors
Countries in which we've closed transactions
Languages spoken by our Team
Total deals value
Global lower-middle market M&A Advisors
Countries in which we've closed transactions
Languages spoken by our Team
Total deals value
© 2024 MergersCorp M&A International.
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
2500件以上の臨床治療で優れた安全性の実績を持つバイオテクノロジー事業。 同社は、アフィニティー血液濾過製品を設計、製造、販売しています。 特許取得済みの独自 ...
インドの製薬産業は過去数十年で世界的なプレーヤーとして台頭し、世界最大のジェネリック医薬品生産者の一つになりました。 インドの医薬品ビジネスは急激な ...
この医薬品製造会社はヨルダンのアンマンで約 40 年前に設立されました。 70 を超える特許を取得し、イノベーションにおける地域のベンチマークを保持しています。 ...
2500件以上の臨床治療で優れた安全性の実績を持つバイオテクノロジー事業。 同社は、アフィニティー血液濾過製品を設計、製造、販売しています。 特許取得済みの独自のバイオミメティック技術を使用して、血流感染症に苦しんでいる患者から細菌、真菌、細菌毒素、ウイルス、炎症誘発性サイトカイン、敗血症メディエーターを迅速に除去する、新しくて非常に革新的な血液濾過装置です。
投資の魅力
毎年 3,000 万件を超える数百万人の患者が世界の敗血症市場に影響を及ぼしています。
この技術の他の用途は、診断、血液銀行業務、およびバイオプロセシングにおける ECMO および心肺バイパスの使用による副作用を防ぐため、生物兵器攻撃 (COVID) や PDAC がんへの対策として使用される可能性があります。
わずか 10 倍の純利益があれば、2028 年末までに同社の価値は最大 400 億ドルに達する可能性があります。
成長の機会
強力な経営
売上総利益率 >85%
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
This website is operated by MergersUS Inc a US Corporation with registered office at
エラー: コンタクトフォームが見つかりません。
エラー: コンタクトフォームが見つかりません。
エラー: コンタクトフォームが見つかりません。
エラー: コンタクトフォームが見つかりません。